IGC Pharma, Inc. (IGC)
IGCAMEXBiotechnology: Pharmaceutical Preparations
$0.2058
+0.0078 (+3.94%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $23.81m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.0800 to $0.4041
- Average volume
- 9.54m
- Previous close
- $0.1980
Analysts
1 coveringHold1 buy, 0 hold, 0 sell
Targets a year out average $6.00, +2815.5% from here
Earnings
next estimate $-0.0200Next report
Mar 2026
0.0%
Jun 2026
-50.0%
Sep 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|
| Revenue | $295.0k | $272.0k | $412.0k | $257.0k |
| Gross profit | $171.0k | $163.0k | $198.0k | $104.0k |
| Operating income | -$2.17m | -$2.40m | -$1.76m | -$1.88m |
| Net income | -$2.88m | -$2.38m | -$1.72m | -$1.83m |
Last four quarters: revenue $1.24m, margin -712.7%, free cash flow -$4.70m
News
8 latest- Guardian Pharmacy Services (GRDN) Q3 Earnings and Revenues Surpass EstimatesZacks · 4 days ago
- IGC Pharma (IGC) Price Target Increased by 10.34% to 4.08Fintel · Mar 27, 2026
- 4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat EstimatesZacks · Mar 18, 2026
- Merck KGaA (MKKGY) Lags Q4 Earnings EstimatesZacks · Mar 5, 2026
- IGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation RTTNews · Dec 10, 2025
- Ascendiant Capital Maintains IGC Pharma (IGC) Buy RecommendationFintel · Dec 9, 2025
- IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue EstimatesZacks · Nov 14, 2025
- Pre-Market Earnings Report for November 17, 2025 : HTHT, ARMK, YMM, JJSF, JKS, CRGO, ARBE, NRXP, IGC, VRMENASDAQ.com · Nov 14, 2025
The company
IGC Pharma is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is currently being evaluated in a Phase 2 CALMA trial for agitation associated with Alzheimer's dementia. The Company's pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, sleep, and metabolic dysfunctions. IGC integrates AI to support drug discovery, clinical trials optimization, and patient targeting.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- Region
- North America
- Website
- igcinc.us
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.